게놈 암 검사 시장 : 검사 유형별, 암 유형별, 기술별, 최종사용자별, 바이오마커 유형별, 서비스 제공업체별, 용도별, 검사 환경별, 지역별
Genomic Cancer Testing Market, By Test Type, By Cancer Type, By Technology, By End-User, By Biomarker Type, By Service Provider, By Application, By Testing Setting, By Geography
상품코드
:
1741184
리서치사
:
Coherent Market Insights
발행일
:
2025년 03월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
게놈 암 검사 시장은 2025년 220억 달러, 2032년에는 648억 5,000만 달러에 이를 것으로 예측되며, 2025-2032년 16.7%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.
| 보고서 범위 |
보고서 상세 |
| 기준 연도 |
2024년 |
2025년 시장 규모 |
220억 달러 |
| 실적 데이터 |
2020-2024년 |
예측 기간 |
2025-2032년 |
| 예측 기간(2025-2032년) CAGR |
16.70% |
2032년 가치 예측 |
648억 5,000만 달러 |
게놈 암 검사는 종양학 분야를 빠르게 변화시키고 있습니다. 이 검사는 암세포의 유전자 구성을 분석하여 환자의 질병을 유발하는 돌연변이에 대한 통찰력을 제공합니다. 이러한 개별화 접근법을 통해 임상의는 개인의 유전자 프로파일에 따라 치료를 조정하고 존재하는 이상을 직접 표적으로 삼는 치료제를 선택할 수 있습니다. 종양 유전체 분석은 특정 약물에 대한 반응을 예측하고, 재발 위험이 높음을 나타내는 유전자 마커를 확인하고, 암 성장을 막기 위해 차단할 수 있는 생물학적 경로를 식별하는 데 도움이 됩니다. 유전체 기술의 지속적인 발전으로 암 검사가 더욱 종합적이고 저렴해지고 있습니다. 이는 향후 몇년안에 많은 암 환자들의 예후를 크게 개선할 수 있을 것으로 기대됩니다.
시장 역학:
세계 게놈 암 검사 시장은 주로 전 세계 암 발병률 증가와 이에 따른 정밀의료 접근법에 대한 수요에 의해 주도되고 있습니다. 바이오마커 식별을 위한 차세대 염기서열 분석(NGS) 기술의 적용이 확대되고 있는 것도 시장 성장을 견인하고 있습니다. 그러나 특히 개발도상국에서는 유전체 분석에 필요한 인프라와 숙련된 전문가 부족이 큰 문제점으로 지적되고 있습니다. 검사 절차의 높은 비용도 보급을 더욱 제한하고 있습니다. 그러나 새로운 진단 도구를 개발하기 위한 민간 및 공공 기관의 자금 지원은 유리한 기회를 제공합니다. 진단 기업과 암센터와의 파트너십은 유전체 프로파일링에 대한 접근성을 확대하는 것을 목표로 하고 있습니다. 실용적인 유전체 변화를 감지하고 동반 진단 약물을 검증하기 위한 기타 전략적 이니셔티브는 게놈 암 검사 시장을 더욱 자극할 것입니다. 또한, 시장 참여자들 간의 협력 관계 강화는 예측 기간 동안 시장 성장을 가속할 것으로 예측됩니다. 예를 들어, 2023년 4월, 인공지능 및 정밀의료 분야의 선도기업인 Tempus는 진행성 또는 전이성 갑상선 수질암(MTC) 또는 진행성 또는 전이성 비갑상선 수질암(비 MTC)을 가진 적격 환자에게 유전체 검사에 대한 접근성을 확대하기 위해 설계된 Eli Lilly and Company가 후원하는 새로운 제휴를 오늘 발표했습니다. 이번 협력은 템포스가 분자 프로파일링을 무료로 제공하고, 의사들과 협력하여 광범위한 유전체 검사를 통해 환자들에게 데이터에 기반한 치료법을 제공할 수 있도록 지원하는 것입니다.
본 조사의 주요 특징
- 이 보고서는 2024년을 기준 연도로 하여 2025-2032년까지의 예측 기간 동안 시장 규모와 연평균 성장률(CAGR%)을 분석하여 세계 게놈 암 검사 시장을 상세하게 연구한 보고서입니다.
- 또한, 다양한 부문에 걸친 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
- 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 게놈 암 검사 시장의 주요 기업을 프로파일링합니다.
- 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 세계 게놈 암 검사 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 게놈 암 검사 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
- 보고서 설명
- 주요 요약
- Coherent Opportunity Map(COM)
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 영향 분석
- 주요 하이라이트
- 규제 시나리오
- 제품 발매 및 승인
- PEST 분석
- PORTER 분석
- 인수합병(M&A) 시나리오
제4장 세계의 게놈 암 검사 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향
- COVID-19 역학
- 공급측과 수요측 분석
- 경제에 대한 영향
제5장 세계의 게놈 암 검사 시장, 검사 유형별, 2020년-2032년
- 유전체 프로파일링 검사
- 액체생검 검사
- 동반진단 검사
- 약물유전체학 검사
- 유전성 암 검사
- 기타 전문적인 유전체 검사
제6장 세계의 게놈 암 검사 시장, 암 유형별, 2020년-2032년
- 유방암
- 폐암
- 대장암
- 전립선암
- 난소암
- 흑색종
- 백혈병
- 림프종
- 기타 특정 암 유형
제7장 세계의 게놈 암 검사 시장, 기술별, 2020년-2032년
- 차세대 시퀀싱(NGS)
- 중합효소 연쇄반응(PCR)
- Fluorescence In Situ Hybridization (FISH)
- 마이크로어레이
- 면역조직화학(IHC)
- 기타 유전체 검사 기술
제8장 세계의 게놈 암 검사 시장, 최종사용자별, 2020년-2032년
- 병원
- 진단실험실
- 학술연구기관
- 암센터
- 기타 의료 제공자
제9장 세계의 게놈 암 검사 시장, 바이오마커 유형별, 2020년-2032년
- 유전자 바이오마커
- 단백질 바이오마커
- 분자 바이오마커
- 에피제네틱 바이오마카
제10장 세계의 게놈 암 검사 시장, 서비스 제공업체별, 2020년-2032년
- 진단실험실
- 바이오테크놀러지 기업
- 제약회사
- 계약연구기관(CRO)
제11장 세계의 게놈 암 검사 시장, 지역별, 2020년-2032년
- 북미
- 라틴아메리카
- 유럽
- 영국
- 독일
- 이탈리아
- 프랑스
- 스페인
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- ASEAN
- 호주
- 한국
- 기타 아시아태평양
- 중동
- 아프리카
제12장 경쟁 구도
- Illumina, Inc.
- Thermo Fisher Scientific, Inc.
- Qiagen N.V.
- F.Hoffmann-La Roche Ltd.
- Foundation Medicine, Inc.(Roche)
- Invitae Corporation
- NeoGenomics Laboratories, Inc.
- Myriad Genetics, Inc.
- Genomic Health, Inc.(Exact Sciences Corporation)
- Caris Life Sciences
- ArcherDX, Inc.(Invitae Corporation)
- Guardant Health, Inc.
- Personal Genome Diagnostics Inc.
- Biocept, Inc.
- Tempus Labs, Inc.
제13장 섹션
LSH
영문 목차
Genomic Cancer Testing Market is estimated to be valued at USD 22.00 Bn in 2025 and is expected to reach USD 64.85 Bn by 2032, growing at a compound annual growth rate (CAGR) of 16.7% from 2025 to 2032.
| Report Coverage |
Report Details |
| Base Year: |
2024 |
Market Size in 2025: |
USD 22.00 Bn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: |
16.70% |
2032 Value Projection: |
USD 64.85 Bn |
Genomic cancer testing is rapidly transforming the field of oncology. It involves analyzing the genetic makeup of cancer cells to gain insights into the mutations driving a patient's disease. This personalized approach enables clinicians to tailor treatment based on an individual's genetic profile and select therapeutics that directly target the abnormalities present. The genomic analysis of a tumor helps predict response to certain drugs, checks for genetic markers that may indicate higher risk of recurrence, and pinpoints biological pathways that can be blocked to stop cancer growth. With continued advances in genomic technologies, cancer testing is becoming more comprehensive and affordable. This is expected to significantly improve outcomes for many cancer patients in the coming years.
Market Dynamics:
The global genomic cancer testing market is primarily driven by rising cancer burden worldwide and subsequent demand for precision medicine approaches. Growing application of next-generation sequencing (NGS) technologies for biomarker identification is also fueling market growth. However, lack of infrastructure and skilled professionals required for genomic analysis poses a major challenge, especially in developing nations. High cost of testing procedures further limits widespread adoption. Yet funding from private and public bodies to develop novel diagnostic tools presents lucrative opportunities. Partnerships between diagnostic companies and cancer centers aim to expand access to genomic profiling. Other strategic initiatives to detect actionable genomic alterations and validate companion diagnostics will further stimulate the genomic cancer testing market. MOrevoer, increasing collaboration between market players is expected to drive the market growth over forecast period. For instance, in April 2023, Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration sponsored by Eli Lilly and Company designed to expand access to genomic testing for eligible patients who have advanced or metastatic medullary thyroid cancer (MTC) OR advanced or metastatic non-medullary thyroid cancer (non-MTC). This collaboration offers Tempus' molecular profiling offerings at no cost while simultaneously working with physicians to support them in providing data-driven treatment to their patients with the use of broad-panel genomic testing.
Key features of the study:
- This report provides in-depth analysis of the global genomic cancer testing market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global genomic cancer testing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Illumina, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., F. Hoffmann-La Roche Ltd., Foundation Medicine, Inc. (Roche), Invitae Corporation, NeoGenomics Laboratories, Inc., Myriad Genetics, Inc., Genomic Health, Inc. (Exact Sciences Corporation), Caris Life Sciences, ArcherDX, Inc. (Invitae Corporation), Guardant Health, Inc., Personal Genome Diagnostics Inc., Biocept, Inc., and Tempus Labs, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global genomic cancer testing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global genomic cancer testing market
Detailed Segmentation:
- Global Genomic Cancer Testing Market, By Test Type:
- Genomic Profiling Tests
- Liquid Biopsy Tests
- Companion Diagnostic Tests
- Pharmacogenomic Tests
- Hereditary Cancer Tests
- Other specialized genomic tests
- Global Genomic Cancer Testing Market, By Cancer Type:
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Ovarian Cancer
- Melanoma
- Leukemia
- Lymphoma
- Other specific cancer types
- Global Genomic Cancer Testing Market, By Technology:
- Next-Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Fluorescence In Situ Hybridization (FISH)
- Microarray
- Immunohistochemistry (IHC)
- Other genomic testing technologies
- Global Genomic Cancer Testing Market, By End User:
- Hospitals
- Diagnostic Laboratories
- Academic and Research Institutions
- Cancer Centers
- Other healthcare providers
- Global Genomic Cancer Testing Market, By Biomarker Type:
- Genetic Biomarkers
- Protein Biomarkers
- Molecular Biomarkers
- Epigenetic Biomarkers
- Global Genomic Cancer Testing Market, By Service Provider:
- Diagnostic Laboratories
- Biotechnology Companies
- Pharmaceutical Companies
- Contract Research Organizations (CROs)
- Global Genomic Cancer Testing Market, By Application:
- Targeted Therapy Selection
- Disease Monitoring
- Prognostic Testing
- Companion Diagnostics
- Risk Assessment
- Pharmacogenomic Testing
- Global Genomic Cancer Testing Market, By Testing Setting:
- In-House Testing
- Outsourced Testing
- Global Genomic Cancer Testing Market, By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
- Company Profiles:
- Illumina, Inc.
- Thermo Fisher Scientific, Inc.
- Qiagen N.V.
- F. Hoffmann-La Roche Ltd.
- Foundation Medicine, Inc. (Roche)
- Invitae Corporation
- NeoGenomics Laboratories, Inc.
- Myriad Genetics, Inc.
- Genomic Health, Inc. (Exact Sciences Corporation)
- Caris Life Sciences
- ArcherDX, Inc. (Invitae Corporation)
- Guardant Health, Inc.
- Personal Genome Diagnostics Inc.
- Biocept, Inc.
- Tempus Labs, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Genomic Cancer Testing, By Test Type
- Market Genomic Cancer Testing, By Cancer Type
- Market Genomic Cancer Testing, By Technology
- Market Genomic Cancer Testing, By End User
- Market Genomic Cancer Testing, By Biomarker Type
- Market Genomic Cancer Testing, By Service Provider
- Market Genomic Cancer Testing, By Application
- Market Genomic Cancer Testing, By Testing Setting
- Market Genomic Cancer Testing, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing Cancer Incidence
- High Costs
- Increasing Cancer Incidence
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Genomic Cancer Testing Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Genomic Cancer Testing Market, By Test Type, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Genomic Profiling Tests
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Liquid Biopsy Tests
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Companion Diagnostic Tests
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Pharmacogenomic Tests
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Hereditary Cancer Tests
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Other specialized genomic tests
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
6. Global Genomic Cancer Testing Market, By Cancer Type, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Prostate Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Ovarian Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Melanoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Lymphoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Other specific cancer types
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
7. Global Genomic Cancer Testing Market, By Technology, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Next-Generation Sequencing (NGS)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Polymerase Chain Reaction (PCR)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Fluorescence In Situ Hybridization (FISH)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Microarray
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Immunohistochemistry (IHC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Other genomic testing technologies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
8. Global Genomic Cancer Testing Market, By End User, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Academic and Research Institutions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Cancer Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Other healthcare providers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
9. Global Genomic Cancer Testing Market, By Biomarker Type, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Genetic Biomarkers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Protein Biomarkers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Molecular Biomarkers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Epigenetic Biomarkers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
10. Global Genomic Cancer Testing Market, By Service Provider, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Biotechnology Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Pharmaceutical Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Contract Research Organizations (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
11. Global Genomic Cancer Testing Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021-2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Service Provider, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Testing Setting, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Service Provider, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Testing Setting, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Service Provider, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Testing Setting, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Service Provider, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Testing Setting, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Service Provider, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Testing Setting, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032,(US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Service Provider, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Testing Setting, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region , 2020-2032,(US$ Bn)
- North Africa
- Central Africa
- South Africa
12. Competitive Landscape
- Illumina, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Thermo Fisher Scientific, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Qiagen N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- F.Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Foundation Medicine, Inc. (Roche)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Invitae Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- NeoGenomics Laboratories, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Myriad Genetics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Genomic Health, Inc. (Exact Sciences Corporation)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Caris Life Sciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- ArcherDX, Inc. (Invitae Corporation)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Guardant Health, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Personal Genome Diagnostics Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Biocept, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Tempus Labs, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
- Analyst Views
13. Section
- Research Methodology
- About us
관련자료
